
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Human Cancer Biology |
Authors' Affiliations: Departments of 1 Cancer Biology and 2 Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston, Texas; and Departments of 3 Surgery and 4 Oncology, University of Michigan, Ann Arbor, Michigan
Requests for reprints: Craig Logsdon, Department of Cancer Biology and Medical Oncology, University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030. Phone: 713-563-3585; E-mail: clogsdon{at}mdanderson.org.
Purpose: In the current study, we examined the functional significance and mechanism of action of S100P in pancreatic cancer cells.
Experimental Design: S100P levels were increased in Panc-1 cells, which do not express S100P, by transfection with an S100P cDNA and S100P levels were reduced in BxPC3 cells, which express high levels of S100P, by small interfering RNA gene silencing. Effects of these manipulations on cell proliferation, resistance to apoptotic insults, cell migration, and invasion were estimated in vitro using standard assays. The influences of S100P on tumor growth in vivo were studied using xenograft mouse models. To identify the mechanisms involved in these responses, coimmunoprecipitation studies were conducted with S100P with receptor for advanced glycation end products (RAGE) and the effects of inhibiting RAGE using an antagonistic peptide were analyzed.
Results: S100P levels correlated with the rates of cell proliferation, survival, migration, and invasion in both cell models in vitro. In vivo, increased S100P levels increased the growth of tumors in mice with s.c.-implanted Panc-1 cells and decreased S100P levels decreased tumor growth after orthotopic implantation of BxPC-3 cells. A direct interaction between S100P and RAGE was indicated by coimmunoprecipitation of these molecules from pancreatic cancer cells. A RAGE antagonist peptide inhibited this interaction and also inhibited the biological effects of S100P on these cells in vitro.
Conclusions: These data suggest that S100P plays a major role in the aggressiveness of pancreatic cancer that is likely mediated by its ability to activate RAGE. Thus, interference with S100P may provide a novel approach for treatment of pancreatic cancer.
This article has been cited by other articles:
![]() |
H. Gu, L. Yang, Q. Sun, B. Zhou, N. Tang, R. Cong, Y. Zeng, and B. Wang Gly82Ser Polymorphism of the Receptor for Advanced Glycation End Products Is Associated with an Increased Risk of Gastric Cancer in a Chinese Population Clin. Cancer Res., June 1, 2008; 14(11): 3627 - 3632. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. R. Reynolds, S. D. Kasteler, M. G. Cosio, A. Sturrock, T. Huecksteadt, and J. R. Hoidal RAGE: developmental expression and positive feedback regulation by Egr-1 during cigarette smoke exposure in pulmonary epithelial cells Am J Physiol Lung Cell Mol Physiol, June 1, 2008; 294(6): L1094 - L1101. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Bulk, A. Hascher, R. Liersch, R. M. Mesters, S. Diederichs, B. Sargin, V. Gerke, M. Hotfilder, J. Vormoor, W. E. Berdel, et al. Adjuvant Therapy with Small Hairpin RNA Interference Prevents Non-Small Cell Lung Cancer Metastasis Development in Mice Cancer Res., March 15, 2008; 68(6): 1896 - 1904. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. F. Hwang, T. Moore, T. Arumugam, V. Ramachandran, K. D. Amos, A. Rivera, B. Ji, D. B. Evans, and C. D. Logsdon Cancer-Associated Stromal Fibroblasts Promote Pancreatic Tumor Progression Cancer Res., February 1, 2008; 68(3): 918 - 926. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Li, U. Bharadwaj, R. Zhang, S. Zhang, H. Mu, W. E. Fisher, F. C. Brunicardi, C. Chen, and Q. Yao Mesothelin is a malignant factor and therapeutic vaccine target for pancreatic cancer Mol. Cancer Ther., February 1, 2008; 7(2): 286 - 296. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Sakaguchi, H. Sonegawa, H. Murata, M. Kitazoe, J.-i. Futami, K. Kataoka, H. Yamada, and N.-h. Huh S100A11, an Dual Mediator for Growth Regulation of Human Keratinocytes Mol. Biol. Cell, January 1, 2008; 19(1): 78 - 85. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. J. Whiteman, M. E. Weeks, S. E. Dowen, S. Barry, J. F. Timms, N. R. Lemoine, and T. Crnogorac-Jurcevic The Role of S100P in the Invasion of Pancreatic Cancer Cells Is Mediated through Cytoskeletal Changes and Regulation of Cathepsin D Cancer Res., September 15, 2007; 67(18): 8633 - 8642. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Ramachandran, T. Arumugam, R. F. Hwang, J. K. Greenson, D. M. Simeone, and C. D. Logsdon Adrenomedullin Is Expressed in Pancreatic Cancer and Stimulates Cell Proliferation and Invasion in an Autocrine Manner via the Adrenomedullin Receptor, ADMR Cancer Res., March 15, 2007; 67(6): 2666 - 2675. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Li, D. G. Heidt, P. Dalerba, C. F. Burant, L. Zhang, V. Adsay, M. Wicha, M. F. Clarke, and D. M. Simeone Identification of Pancreatic Cancer Stem Cells Cancer Res., February 1, 2007; 67(3): 1030 - 1037. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Arumugam, V. Ramachandran, and C. D. Logsdon Effect of Cromolyn on S100P Interactions With RAGE and Pancreatic Cancer Growth and Invasion in Mouse Models J Natl Cancer Inst, December 20, 2006; 98(24): 1806 - 1818. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Ohuchida, K. Mizumoto, T. Egami, H. Yamaguchi, K. Fujii, H. Konomi, E. Nagai, K. Yamaguchi, M. Tsuneyoshi, and M. Tanaka S100P Is an Early Developmental Marker of Pancreatic Carcinogenesis. Clin. Cancer Res., September 15, 2006; 12(18): 5411 - 5416. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Cell Growth & Differentiation |